Sign in or Register
  • Home
    • The story of Aurigene
    • The Aurigene approach
    • Our impact
    • Media center
    • Our publications
  • About Us
    • Our journey
    • Our purpose
    • Our milestones
    • Management Team
    • Board of Directors
  • Science
    • Science
      • Our research
      • Our platform technologies
      • Our publications
    • Pipeline
      • Proprietary Pipeline
      • Partnered Programs in Clinic
  • News and Events
    • Aurigene in the media
    • News
    • Events
  • Careers
    • Life at Aurigene
    • Working at Aurigene
    • Perks at Aurigene
    • Teamwork
    • Current Openings
    • A word from Aurigeneans
  • Contact Us
Aurigene
Home
  • Home
    • The story of Aurigene
    • The Aurigene approach
    • Our impact
    • Media center
    • Our publications
  • About Us
    • Our journey
    • Our purpose
    • Our milestones
    • Management Team
    • Board of Directors
  • Science
    • Science
      • Our research
      • Our platform technologies
      • Our publications
    • Pipeline
      • Proprietary Pipeline
      • Partnered Programs in Clinic
  • News and Events
    • Aurigene in the media
    • News
    • Events
  • Careers
    • Life at Aurigene
    • Working at Aurigene
    • Perks at Aurigene
    • Teamwork
    • Current Openings
    • A word from Aurigeneans
  • Contact Us

Aurigene, a wholly owned subsidiary of Dr Reddy’s, and Curis announce CA-170 program update following data presented at ESMO 2017

  1. Home
  2. news-2017
September 12, 2017
by admin-aurigene

Aurigene, a wholly owned subsidiary of Dr Reddy’s, and Curis announce CA-170 program update following data presented at ESMO 2017

Aurigene, a wholly owned subsidiary of Dr Reddy’s, and Curis announce CA-170 program update following data presented at ESMO 2017 — Results from 34 patients demonstrate positive safety profile and
April 27, 2017
by admin-aurigene

Agios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer Metabolism Target

CAMBRIDGE, Mass., April 27, 2017 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and Aurigene Discovery Technologies Limited today announced a global license agreement to research, develop and commercialize small molecule inhibitors of an undisclosed cancer metabolism
Home
  • Pipeline
  • Publications
  • Science
  • News and Events
  • Careers
Careers
Contact Us

Governance

Code of Business Conduct and Ethics

  • Statement of Policy
  • Link to Raise Concerns

Annual Reports

  • Link to View Report

Safety, Health, Environment and Sustainability

  • Policy Statement and Reports

Policies

CSR

  • Statement of Policy
  • Guiding Principles
  • Activities

Remuneration Policy

  • Statement of Policy

© 2022 Aurigene Discovery Technologies

Privacy & GDPR policy

Cookie policy

Crafted by: Pink Lemonade Communications Pvt. Ltd.

© 2022 Aurigene Oncology

Privacy and GDPR Policy

Cookie Policy

Apply Now